Despite animal studies demonstrating profound and sustainable weight reduction and amelioration of insulin resistance [24], the vision of providing an adiponectin adjunct against human obesity and insulin resistance has not been transcended into clinical trials. The gene discussed is ADIPOQ; the disease is obesity disorder.